Business Overview: Dyadic International, Inc. (NASDAQ: DYAI)

---

Executive Summary

Dyadic International, Inc., headquartered in Jupiter, Florida with a satellite office in the Netherlands, is a global biotechnology platform company. It spent over two decades developing a gene expression platform for industrial enzymes, sold that industrial business to Danisco (DuPont) in 2015, and retained co-exclusive rights to its C1 fungal expression platform for human and animal pharmaceutical applications. It is now a pre-revenue, pre-commercial biopharmaceutical platform company licensing and co-developing C1-based biologics (vaccines, antibodies, therapeutic proteins) and Dapibus™-based non-pharmaceutical proteins (food, nutrition, wellness).

The company matters as a platform/technology licensor rather than a product company — its value depends on whether partners adopt and successfully commercialize products built on its microbial expression technology.

---

1. Core Business Model & How They Work

Dyadic does not sell a commercial product; it licenses its C1 and Dapibus platforms, co-develops programs with partners and government/academic collaborators, and earns milestone, licensing, and potential royalty revenue.

[ C1/Dapibus Platform R&D (VTT, internal) ] ➡️ [ Partner/Government-Funded Collaborations ] ➡️ [ Licensing & Sublicensing Agreements ] ➡️ [ Upfront Payments, Milestones, Future Royalties ]

Key Operational Drivers

1. C1 Platform: Based on the thermophilic fungus Thermothelomyces heterothallica, claimed by the company to offer purity (no viral/endotoxin removal needed), productivity (high yields, low viscosity), speed (~12-14 day production vs. 41-54 days for CHO), and cost (media <1/20 the cost of CHO) advantages versus mammalian (CHO) systems — claims not independently verified in the filing.
2. DYAI-100 Vaccine Proof-of-Concept: A Phase 1 SARS-CoV-2 RBD vaccine candidate, the first C1-expressed protein tested in humans, met its primary safety endpoint and induced immune responses (reported November 2023); further trials depend on partner funding.
3. Broad Partner Network: Collaborations span animal health (Phibro/Abic), human health/government (Rubic One Health, Israel Institute for Biological Research, Massachusetts General Hospital's Vaccine and Immunotherapy Center under DoD funding, Rabian BV), and biopharma (an undisclosed top-ten pharmaceutical company, an undisclosed global biopharma, bYoRNA, Cygnus Technologies/Maravai).
4. IP-Centric Strategy: Seven patent families (five national phase, two PCT), one issued U.S. patent, five pending U.S. applications, and 18 additional international applications, plus trade-secret protection.

---

2. Business Segments

Dyadic operates as a single platform-technology business, organized around pharmaceutical and non-pharmaceutical applications rather than formal reportable segments.

┌───────────────────────────────┐
│    Dyadic International, Inc.    │
└───────────────┬─────────────────┘
                │
     ┌──────────┴───────────┐
     ▼                       ▼
┌─────────────────────┐  ┌──────────────────────┐
│ Biopharma (C1)          │  │ Non-Pharma (Dapibus™)   │
│ Vaccines, antibodies,   │  │ Cell culture media,       │
│ therapeutic proteins,   │  │ non-animal dairy          │
│ biosimilars              │  │ proteins, bio-industrial  │
│                          │  │ enzymes                   │
└─────────────────────┘  └──────────────────────┘

---

3. Product Portfolio

---

4. Competitive Landscape

Item 1 names no specific competitor companies but identifies competing technologies: CHO (mammalian, described as dominant), E. coli (bacterial), Pichia pastoris (yeast), and insect/Baculovirus systems. The filing states Dyadic is not aware of other companies pursuing a similar biopharma business model based on filamentous fungi, though it acknowledges several other firms use filamentous fungi for non-pharma protein production.

   PROTEIN EXPRESSION PLATFORM LANDSCAPE
┌────────────────────────────────────────────┐
│ High │   [CHO - dominant, mammalian]         │
│  M   │                                       │
│  a   │                                       │
│  r   │   [Pichia] [E. coli] [Baculovirus]    │
│  k   │                                       │
│  e   │           [Dyadic C1 - niche,         │
│  t   │            claimed cost/speed edge]    │
│ Low  │                                       │
│      └─────────────────────────────────────►│
│       Niche                  Established Use  │
└────────────────────────────────────────────┘

---

5. Strategic Strengths & Risks

Strengths (The Moat)

• Patent portfolio: seven patent families plus an issued U.S. patent and a Notice of Allowance for a flu-vaccine-production patent with expected protection through 2038.
• Two decades of platform development and a prior successful industrial licensing track record (Abengoa, BASF, Codexis) lend credibility to the technology.
• Diverse, partner-funded pipeline: government and corporate collaborators (NIIMBL/American Rescue Plan grant, DoD-funded MGH work) subsidize R&D costs.
• Claimed cost/speed advantages versus CHO, if validated at commercial scale, could be a meaningful structural edge in biologics manufacturing economics.

Risks

• Pre-revenue, pre-commercial: no product has been commercialized; the biopharma market for fungal-expressed proteins is not yet established.
• Heavy reliance on third parties: CROs, collaborators, and licensees drive most R&D progress, and further trials (e.g., DYAI-100 Phase 2/3) require partner funding the company does not plan to provide itself.
• Tiny organization: only 7 full-time employees as of year-end 2023, concentrating execution risk.
• Related-party financing: $6.0 million in convertible notes (March 2024) were purchased substantially by entities tied to CEO Mark Emalfarb.
• Unverified performance claims: cost/speed/purity advantages are the company's own assertions, not independently confirmed in the filing.
• Danisco rights overhang: uncertain royalty obligations and retained pharmaceutical rights tied to the 2015 Danisco transaction.

---

6. Financial Overview

---

7. Summary Conclusion

Dyadic International is a platform-licensing biotech whose moat, to the extent one exists, rests on a genuine and growing patent portfolio and two decades of fungal-expression know-how that the company believes no direct competitor is replicating in the same biopharma business model. Encouraging early human safety data for DYAI-100 and a broadening set of funded collaborations are real progress markers, but with zero product revenue, only 7 employees, and continued dependence on partner funding and insider-sourced financing, the company's commercial validation — and therefore the durability of any competitive advantage — remains unproven.